Predictive Values of the Human Immunodeficiency Virus Phenotype and Genotype and of Amprenavir and Lopinavir Inhibitory Quotients in Heavily Pretreated Patients on a Ritonavir-Boosted Dual-Protease-Inhibitor Regimen

Ítems similars

• Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients
  per: Taburet, Anne-Marie, et al.
  Publicat: (2004)
• Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir
  per: Duval, Xavier, et al.
  Publicat: (2002)
• Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients
  per: Marcelin, Anne-Geneviève, et al.
  Publicat: (2005)
• Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
  per: Delaugerre, Constance, et al.
  Publicat: (2009)
• Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir
  per: Sale, Mark, et al.
  Publicat: (2002)